Shots:

• United healthcare will update its preferred product coverage criteria in its White Blood Cell Colony Stimulating Factors medical drug policy i.e- it prefers the use of Neulasta Onpro and Neulasta vial over Fulphila and Udenyca
• Additionally- UH will expand its authorization requirements on these medications intended for any diagnosis
• For both UnitedHealthcare commercial and Community Plan members- current authorizations will be honored through their end date. The policies will be updated after authorization renewal

Click here to read full press release/ article | Ref: Center for Biosimilars | Image: UnitedHealthcare